Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus VERSAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN IN PLASTIC CONTAINER versus VERSAPEN.
UNIPEN IN PLASTIC CONTAINER vs VERSAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
500 mg IV every 6 hours or 1 g IV every 8 hours for moderate infections; 2 g IV every 4 hours for severe infections.
None Documented
None Documented
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in anuria. Requires dose adjustment in renal impairment.
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Renal: 60-70% unchanged via glomerular filtration and tubular secretion. Biliary: <10% excreted unchanged. Fecal: 20-30% as metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic